BioInvent (Sweden)

BioInvent (Sweden)

BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for BioInvent (Sweden), Sweden, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

51%


Total
Publications

114


Total Open
Publications

58


Total
Citations

4K


Open Access
Percentage

51%


Total
Publications

114


Total Open
Publications

58


Total
Citations

4K

Wikipedia

Website

download

Breakdown

18% 28% 5% 49%

Publisher Open

18%

Both

28%

Other Platform Open

5%

Closed

49%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0123456789101112Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

38%OA Journal

OA Journal 38%

20

Hybrid 31%

16

No Guarantees 31%

16

Other Platform Open

Domain 79%

30

Institution 42%

16

Public 16%

6

Preprint 8%

3

Other Internet 8%

3

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
30
Europe PMC
Domain
19
University of Southampton - ePrints Soton
Institution
10
Semantic Scholar
Public
5
University of Cambridge - Apollo
Institution
4
bioRxiv
Preprint
3
University of Southern Denmark - University of Southern Denmark Research Portal
Institution
2
University of Leicester - Leicester Research Archive
Institution
2
University of Bath - University of Bath Research Portal
Institution
2
University College London - UCL Discovery
Institution
2
1 / 2

Data updated 7 April 2025

Share

Share

Share